Apellis制药

Apellis's 15min chart triggers MACD Death Cross and KDJ Death Cross signals.

Apellis Pharmaceuticals: JP Morgan Reiterates Overweight, Raises Price Target to $37.

Apellis's stock price triggers Bollinger Bands Narrowing and KDJ Death Cross.

Apellis: Mizuho maintains Neutral, PT raised to $20 from $19.

Catalyst<ul> <li>Analysts rate APLS as Strong Buy or Buy, indicating institutional confidence in the stock despite some valuation concerns.</li></ul>Risk<ul> <li>Technical indicators suggest a volatile market with unclear direction, and bearish signals such as Dark Cloud Cover and Long Upper Shadow suggest potential downward pressure on APLS.</li> <li>Fund flow data indicates net outflows in most buckets except Extra-large, suggesting caution among smaller and mid-sized investors.</li></ul>

Key Factors

JPMorgan analyst Anupam Rama raised his price target for Apellis to $37, maintaining an Overweight rating and highlighting the stock as a strategic overweight in the biotech sector.

APLS News